Literature DB >> 2573904

Memory facilitation produced by dopamine agonists: role of receptor subtype and mnemonic requirements.

M G Packard1, N M White.   

Abstract

The role of dopamine (DA) receptor subtypes in the acquisition of two memory tasks in the 8-arm radial maze was examined. The receptors were manipulated with posttraining, subcutaneous injections of an indirect DA receptor agonist (D-amphetamine), a selective D2 receptor agonist (LY171555), and a selective D1 receptor agonist (SKF-38393). On a win-stay task (sensitive to caudate nucleus lesions) a light cue signalled the location of food in 4 randomly selected arms on each trial. Rats were given one trial per day and injected after training on day 5. D-Amphetamine (2.0 mg/kg) and LY171555 (2.0 mg/kg) improved performance relative to controls; however SKF-38393 (1-4 mg/kg) had no effect on the acquisition of win-stay behavior. On a win-shift task (sensitive to fornix/hippocampal lesions) a delay of 18 hr was imposed between the first 4 and second 4 choices; drugs were injected after the first 4 choices. D-Amphetamine (1.0 mg/kg) and LY171555 (2.0 mg/kg) significantly improved retention relative to controls. SKF-38393 (1-4 mg/kg) had no effect on win-shift retention. These results suggest that the memory-improving properties of DA agonists on tasks sensitive to both hippocampal and caudate lesions are mediated by the D2 receptor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573904     DOI: 10.1016/0091-3057(89)90378-x

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  22 in total

1.  Delayed-non-match-to-sample performance in the radial arm maze: effects of dopaminergic and gabaergic agents.

Authors:  J J Chrobak; T C Napier
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Post-training, but not post-reactivation, administration of amphetamine and anisomycin modulates Pavlovian conditioned approach.

Authors:  Cory A Blaiss; Patricia H Janak
Journal:  Neurobiol Learn Mem       Date:  2007-01-26       Impact factor: 2.877

4.  Burst activation of dopamine neurons produces prolonged post-burst availability of actively released dopamine.

Authors:  Sweyta Lohani; Adria K Martig; Suzanne M Underhill; Alicia DeFrancesco; Melanie J Roberts; Linda Rinaman; Susan Amara; Bita Moghaddam
Journal:  Neuropsychopharmacology       Date:  2018-05-07       Impact factor: 7.853

5.  Drugs of abuse as memory modulators: a study of cocaine in rats.

Authors:  Nabeel Rkieh; Jacob M Cloke; Nicola Gallagher; Boyer D Winters; Francesco Leri
Journal:  Psychopharmacology (Berl)       Date:  2013-12-13       Impact factor: 4.530

6.  Kappa Opioid Receptor-Mediated Disruption of Novel Object Recognition: Relevance for Psychostimulant Treatment.

Authors:  Jason J Paris; Kate J Reilley; Jay P McLaughlin
Journal:  J Addict Res Ther       Date:  2011-12-24

7.  Enhancing effect of heroin on social recognition learning in male Sprague-Dawley rats: modulation by heroin pre-exposure.

Authors:  Annemarie Levy; Elena Choleris; Francesco Leri
Journal:  Psychopharmacology (Berl)       Date:  2009-01-29       Impact factor: 4.530

8.  Effects of persistent cocaine self-administration on amygdala-dependent and dorsal striatum-dependent learning in rats.

Authors:  Tomoko Udo; Francisco Ugalde; Nina DiPietro; Howard B Eichenbaum; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

9.  Motor and cognitive functions of the neostriatum during bilateral blockade of its dopamine receptors.

Authors:  K B Shapovalova; Yu V Kamkina
Journal:  Neurosci Behav Physiol       Date:  2008-01

10.  Local hippocampal methamphetamine-induced reinforcement.

Authors:  Ulises M Ricoy; Joe L Martinez
Journal:  Front Behav Neurosci       Date:  2009-11-16       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.